文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症COVID-19患者中不同临床亚型的识别

Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19.
PubMed 文献 · Chest · 2021-05-06
一句话结论多中心队列中潜伏类别分析识别出重症COVID-19的4种亚型,28天死亡率从20.6%(SP4)到52.9%(SP1)不等,校正后SP1、SP2、SP3死亡风险仍高于SP4。

本研究基于美国67家医院的多中心队列,纳入重症COVID-19患者,将中心随机分为发现队列(45家中心,n=2188)和重复队列(22家中心,n=1112),分别在每个队列中独立使用潜伏类别分析,基于临床和实验室变量识别亚型,并分析亚型与28天死亡率的关系。结果识别出4种亚型(SP1-SP4),特征在发现队列和重复队列中一致。发现队列28天死亡率从20.6%(SP4)到52.9%(SP1)不等,校正人口学、合并症、器官功能障碍和疾病严重程度、区域和医院因素后,亚型间死亡率仍有差异;与SP4相比,SP1相对风险1.67(95%CI 1.36-2.03),SP2为1.39(95%CI 1.17-1.65),SP3为1.39(95%CI 1.15-1.67)。重复队列结果相似。

要点

  • 发现队列(45家中心,n=2188)中28天死亡率从20.6%(SP4)到52.9%(SP1)不等。
  • 与SP4相比,校正后SP1相对风险1.67(95%CI 1.36-2.03),SP2为1.39(95%CI 1.17-1.65),SP3为1.39(95%CI 1.15-1.67)。
  • SP1特征为休克、酸血症和多器官功能障碍,包括需要肾脏替代治疗的急性肾损伤。
  • SP2特征为高C反应蛋白、早期需要机械通气、ARDS发生率最高。
  • SP3慢性病负担最高,SP4慢性病负担有限且生理异常轻微;重复队列(22家中心,n=1112)结果相似。

适用人群与场景

  • 美国67家医院重症COVID-19患者,纳入发现队列(45家中心,n=2188)和重复队列(22家中心,n=1112)

研究设计与关键结果

  • 研究类型:多中心队列研究,中心随机分为发现队列和重复队列,分别独立进行潜伏类别分析。
  • 发现队列45家中心,n=2188;重复队列22家中心,n=1112;基于临床和实验室变量识别出4种亚型(SP1-SP4),特征在两个队列中一致。
  • SP1特征为休克、酸血症和多器官功能障碍,包括需要肾脏替代治疗的急性肾损伤;SP2特征为高C反应蛋白、早期需要机械通气、ARDS发生率最高;SP3慢性病负担最高;SP4慢性病负担有限且生理异常轻微。
  • 发现队列28天死亡率从20.6%(SP4)到52.9%(SP1)不等;校正人口学、合并症、器官功能障碍和疾病严重程度、区域和医院因素后,亚型间死亡率仍有差异。
  • 与SP4相比,相对风险:SP1为1.67(95%CI 1.36-2.03);SP2为1.39(95%CI 1.17-1.65);SP3为1.39(95%CI 1.15-1.67)。
  • 重复队列结果与发现队列相似。

证据类型、等级与局限

  • 证据类型:多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Subphenotypes have been identified in patients with sepsis and ARDS and are associated with different outcomes and responses to therapies.

RESEARCH QUESTION: Can unique subphenotypes be identified among critically ill patients with COVID-19?

STUDY DESIGN AND METHODS: Using data from a multicenter cohort study that enrolled critically ill patients with COVID-19 from 67 hospitals across the United States, we randomly divided centers into discovery and replication cohorts. We used latent class analysis independently in each cohort to identify subphenotypes based on clinical and laboratory variables. We then analyzed the associations of subphenotypes with 28-day mortality.

RESULTS: Latent class analysis identified four subphenotypes (SP) with consistent characteristics across the discovery (45 centers; n = 2,188) and replication (22 centers; n = 1,112) cohorts. SP1 was characterized by shock, acidemia, and multiorgan dysfunction, including acute kidney injury treated with renal replacement therapy. SP2 was characterized by high C-reactive protein, early need for mechanical ventilation, and the highest rate of ARDS. SP3 showed the highest burden of chronic diseases, whereas SP4 demonstrated limited chronic disease burden and mild physiologic abnormalities. Twenty-eight-day mortality in the discovery cohort ranged from 20.6% (SP4) to 52.9% (SP1). Mortality across subphenotypes remained different after adjustment for demographics, comorbidities, organ dysfunction and illness severity, regional and hospital factors. Compared with SP4, the relative risks were as follows: SP1, 1.67 (95% CI, 1.36-2.03); SP2, 1.39 (95% CI, 1.17-1.65); and SP3, 1.39 (95% CI, 1.15-1.67). Findings were similar in the replication cohort.

INTERPRETATION: We identified four subphenotypes of COVID-19 critical illness with distinct patterns of clinical and laboratory characteristics, comorbidity burden, and mortality.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Vasquez CR, Gupta S, Miano TA, et al. Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest. 2021. PMID: 33964301. doi:10.1016/j.chest.2021.04.062

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。